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Abstract
BACKGROUND: The misuse and overuse of antibiotics contribute to the development of antimicrobial residence. 
Official data in EU/ EEA in 2017 in the hospital sector suggested that the consumption is lowest in the Netherlands, 
with 1 DDD per 1,000 inhabitants/day in comparison with Finland, with 2.8 DDD/TID. 
AIM: The aim of this study was to analyze data on the scope and structure of the antibiotic prescription in pediatric 
patients at University Children’s Hospital for period of 3 months in 2018 and 2019. 
MATERIALS AND METHODS: The data for antibiotic consumption were obtained from a hospital pharmacy, which 
are ordinated to hospitalized patients. 
RESULTS: The total amount of utilized antibacterial drugs with ATC code J01 for first quarter in 2018 is 33.65 
DDD/100BD in comparison to the first quarter of 2019 when it declined to 32.09 DDD/100BD. The most consummated 
antibiotics in the first trimester of both years were the group of cephalosporins, especially the 3rd- and 4th-generation 
parenteral cephalosporins with from 16.96 to 19.25 DDD/100BD in the evaluated period. Decrease of penicillin’s, 
carbapenems, macrolides and quinolones were confirmed in the analyzed period. The most commonly used drugs 
remain ceftriaxone – 13.49 DDD/100BD in 2018 and increased to 14.41 DDD/100BD in 2019, followed by amikacin 
3.21 DDD/100BD in 2018 and increased to 3.50 DDD/100BD in 2019 but azithromycin consumption significantly 
declined from 1.97 DDD/100BD to 0.81 DDD/100BD administered orally. The third most commonly utilized antibiotic 
in first quarter of 2019 become meropenem, antimicrobial drug from the group of carbapenems with 2.71 DDD/100BD. 
CONCLUSION: The benefits of monitoring the antibiotic prescribed pattern are critical due to the fact that they 
provide adequate data on consumption of antibiotics and adherence to guidelines.
Introduction
The misuse and overuse of antibiotics contribute 
to the development of antimicrobial resistance. Incidence 
of serious infections caused by multidrug-resistant 
microorganisms has increased; multidrug-resistance 
microorganisms continue to pose a serious threat for 
the public health as they do not respond to conventional 
treatment. It is estimated that in the EU countries two million 
people were hospitalized due to infectious diseases, and 
about two hundred thousand died annually [1]. According 
to the official data for EU/EEA in 2017, the average 
consumption of antibiotics for systemic use (outside of 
hospitals) was 21.8 defined daily dose/1000 inhabitants/
day (DDD/TID) (10.1 in Nederland to 33.6 in Cyprus). In 
the hospital sector, official data suggested that variations 
are much smaller with the lowest consumption is in the 
Netherlands, with 1 DDD/1000 inhabitant per day to 2.8 
DDD in Finland. On average, hospitals in the EU spend 2 
DDD/1000 inhabitants. Still over 90% of the consumption 
of antimicrobial drugs is outside of hospitals. Most 
frequently prescribed were penicillin’s in combination with 
β-lactamase inhibitors, broad-spectrum penicillin’s, and 
cephalosporins followed by macrolides and tetracyclines 
[2]. Significant differences in prescribing habits were 
identified among the EU countries for the type and 
quantity of antibacterial drugs. Evident differences were 
identified for the prescription of beta-lactamase sensitive 
penicillin’s (natural penicillin and aminopenicillins) within 
the EU. Furthermore, the consumption ratio of broad-
spectrum penicillin’s, cephalosporins, and macrolides 
with that of narrow-spectrum penicillin’s, cephalosporins, 
and macrolides in the EU/EEA was 2.3 [3].
In the Republic of North Macedonia, according 
to the Health Insurance Fund (HIF) data, in the 
period 2012–2018, the consumption of prescription 
antimicrobials in primary health care ranged from 17 to 
about 20 DDD per 1000 insured persons. These data 
do not cover antibiotics purchased by private insurers 
or patients on their own.
The data obtained by Health Insurance Fund 
(HIF) of the Republic of North Macedonia, the share 
of beta-lactamase-sensitive penicillin’s is 14.5% of 
the total prescribed antimicrobial drugs in the period 
2012–2018. The ratio of broad-spectrum versus 
narrow-spectrum penicillins is 2. In the second place 
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of the prescribed, antibiotics are cephalosporins with 
an average of about 456 000 prescriptions (2.22%), 
fluoroquinolones 265 000 (1.24%), and macrolides 
with an average of 244000 (1.19%) prescriptions/
year. Tetracyclines, which are in the third place in 
the EU, are in the last place in the Republic of North 
Macedonia, after the prescriptions for cotrimoxazole 
0.3% (60 000) and lincosamides 0.16% (32.000), with 
about 3 000 (0.014%) prescriptions for doxycycline [4].
The average number of prescriptions for 
antibacterial drugs prescribed annually was about 1.9 
million in the evaluated period. According to the most 
optimistic estimates, the total consumption of antibiotics 
in the Republic of North Macedonia would be around 30 
DDD per 1000 inhabitants, and together with hospital 
medicines, it is assumed to be around 32 DDD per 1000 
inhabitants. The most pessimistic estimates are that the 
total consumption of antimicrobial drugs in the Republic 
of North Macedonia is up to 40 DDD per 1000 inhabitants 
(4 of 100 inhabitants use antibiotics every day). Almost 
one-third of the prescribed drugs are amoxicillin-
clavulanic acid and the number of prescriptions exceeded 
500,000 in 2014 or over 5 DDD/1000 inhabitants. Having 
in consideration the DDDs of antimicrobial drugs that 
the patients are buying in pharmacies outside health 
insurance, it could be approximated that up to 10 
DDDs/1000 inhabitants are consumed, which would be 
almost the same as the total consumption of all systemic 
antibacterial drugs used in the Netherlands (11 DDDs 
ambulatory primary care and 1DDD in-hospital) [3].
Monitoring the prescription of antibiotics is 
of crucial importance, due to more distinct bacterial 
resistance, the occurrence of adverse reactions and 
treatment costs. A particular challenge is monitoring the 
usage of antibiotics and the resistance of bacteria in hospital 
settings with a pediatric population [5], [6], [7], [8], [9].
Bacteria isolated in biological samples from 
children under the age of two shows a higher percentage 
of antibiotic resistance compared to bacteria isolated in 
older children while isolates obtained from the hospitals 
are more resistant in comparison to the isolates from 
primary care [10], [11], [12], [13].
The Anatomical Therapeutic Chemical 
Classification/Defined Daily Dose (ATC/DDD) system is 
the standard method for measuring the consumption of 
drugs that allow analyses and comparing consumption 
between different countries, regions, and health-care 
institutions [14], [15]. Drug consumption in hospitals is 
expressed with the DDD/100BD statistical unit, where 
the used antibiotics expressed in daily defined doses-
DDD are correlated with the number of hospitals spent 
days-BD (bed/day) in a given period of time.
The study monitors the consumption of 
systemic antibiotics that are classified according to the 
ATC classification as J01 – antibiotics for systemic use. 
DDD is a statistical unit for monitoring the usage of 
medical products that expresses the average daily dose 
of the specified drug for the most common indication for 
which it is used.
There are several reasons for different 
levels of resistance that includes antibiotic use, more 
difficult diseases to diagnose, quality of hospital care, 
immunization rate, and social factors in the country. It is 
not always possible to determine the ratio of resistant 
infections caused by each individual factor. Data from the 
European Antimicrobial Resistance Data Surveillance 
System show that countries in northern Europe, such as 
the Scandinavian countries and the Netherlands, have 
a low rate of resistance, and in countries, in the southern 
parts of Europe, the rate is higher. Countries with a low 
rate of resistance to antibiotics have generally lower 
use of antimicrobials and, by analogy, countries with 
a higher degree of resistance use more antibiotics [3]. 
The data on the antibiotic consumption and bacterial 
resistance in the hospitalized pediatric population in the 
Republic of North Macedonia are limited.
The conducted study aims to evaluate and 
compare the antibiotics consumption in the pediatric 
hospitalized population at the University Clinic for Pediatric 
Diseases in Skopje for a period of 3 months in the year 
2018 and 2019 based on hospital departments’ data.
Materials and Methods
The observational pharmacoepidemiological 
study was conducted at the University Clinic for Pediatric 
Diseases in Skopje. The data for antibiotics consumption 
were obtained from the hospital pharmacy, in the study, 
we have compared the antibiotics consumption between 
the Quarter 1 (January, February, and March) of 2018 
and Quarter 1 (January, February, and March) of 2019.
The University Clinic for Pediatric Diseases 
in Skopje is tertiary health-care institution with 
177 hospital beds, divided in the following twelve 
departments: Hematology, oncology, pulmonology, 
endocrinology and genetics, immunology, neonatology, 
gastroenterohepatology, infant, metabolism and cystic 
fibrosis, cardiology with rheumatology, nephrology, 
neurology, and intensive care. The number of 
hospitalized patients in Quarter 1 (January, February, 
and March) of 2018 and Quarter 1 (January, February, 
and March) of 2019 is presented in Table 1.
Consumption of systemic antibiotics was 
evaluated based on dispensed systemic antibiotics 
J01 (regardless of the indication for which they were 
used – prophylaxis or therapy) for each department 
provided from the hospital pharmacy information 
system (assessed by type and volume, departments, 
ATC classification, and generic drug name). Total 
spent hospital days (bed/day) BD– i.e. the number 
of hospitalizations per day during a certain period of 
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time and the index of occupancy of hospital beds were 
collected on a monthly basis from the Clinic.
The quantity of antimicrobial drugs was 
converted into a number of defined daily doses (DDD/100 
bed-days (DBD) through the anatomical-therapeutic-
chemical (ATC) and DDD drug classification [16].
Antibiotics consumption in the hospital 
(DDD/100BD) was calculated with the following formula:
DDD BD = Number of spent units antibiotic (mg)
DDD (mg) No.
/ 100
×  of days  No. of beds
beds
Indexof occupied beds
×
×
100
Results
The total amount of utilized antibacterial drugs 
with ATC code J01 for the first quarter (3 months – 
January, February, and March 2018) at the University 
Clinic for Pediatric Diseases in Skopje was 33.65 
DDD/100BD in comparison to the first quarter of 2019 
when it declined to 32.09 DDD/100BD. The evaluation 
of antibiotics consumption in the first Quarter of 2018 
versus 2019 was performed after the implementation 
of restriction policy and control of the prescription 
of certain antibiotics. The results are presented in 
Table 2.
As presented in Table 2, the most frequently 
utilized antibiotics were the group of cephalosporins, 
in both Q1-2018 and Q1-2019. There was an evident 
reduction of consumption of the first and second 
generation of cephalosporins (cefadroxil 0.28 
DDD/100BD in 2018 versus 0.16 DDD/100BD in 
2019 and twofold declination of consumption of the 
oral form of cefaclor from 0.18 DDD/100BD in 2018 
to 0.09 DDD/100BD in 2019). The evident increase 
was evaluated in the use of 3rd and 4th generation of 
cephalosporins (cefotaxime from 0.18 DDD/100BD to 
2.15 DDD/100BD ceftriaxone from 13.49 DDD/100BD 
to 14.41 DDD/100BD and cefepime from 0.60 to 0.68 
DDD/100BD in the first quarter of 2018 vs. same period 
of 2019, respectively). All the above-mentioned resulted 
in a total increase of cephalosporin consumption from 
16.96 to 19.25 DDD/100BD in the same period in 
2018 1nd 2019 in the clinic. Declination in the group 
of carbapenems consumption was noticed (3.44 
DDD/100BD in 2018 vs. 3.01 DDD/100BD in 2019), 
as a result of significant declination of combination 
imipenem, cilastatin from 1.56 to 0.30 DDD/100BD, 
although the consumption of meropenem increased 
for 0.83 DDD/100BD in the evaluated period. Evident 
declination of penicillin’s consumption was established 
in evaluated quarters in the year 2018 versus 
2019, from 3.44 to 2.27 DDD/100BD, respectively. 
Decrease of penicillin consumption was result of 
significant declination of broad-spectrum penicillin’s 
(amoxicillin), beta-lactamase sensitive (benzathine 
phenoxymethylpenicillin), and combined penicillin’s with 
beta-lactamase inhibitors (amoxicillin and clavulanic 
acid) consumption. Regarding macrolides consumption, 
midecamycin was introduced in 2019 as a therapeutic 
option searing 0.11 DDD/100BD in the first quarter of 
2019 and declination of azithromycin for more than 1 
DDD/100BD (1.97 in 2018 vs., 0.81 DDD/100BD in 
2019) resulting in an overall decrease of macrolides 
consumption from 1.97 to 0.92 DDD/100BD in 2019. 
The therapeutic use of clindamycin remains the same 
Table 2: Antibiotic consumption in the first quarters of 2018 and 
2019 at the University Clinic for Pediatric Diseases in Skopje
ATC Form Q1/2018 Q1/2019
J01CA01 Parenteral 0.89 0.97
J01CA04 Oral 0.45 0.09
JOICA  1.33 1.07
J01CE10 Oral 0.15 0.05
J01CF02 Oral 0.88 0.51
J01CR02 Oral 0.82 0.42
J01CR05 Parenteral 0.26 0.23
JOIC  3.44 2.27
J01DB05 Oral 0.28 0.16
J01DB  0.28 0.16
J01DC02 Parenteral 0.00 0.01
J01DC04 Oral 0.18 0.09
J01DC  0.18 0.10
J01DD01 Parenteral 0.18 2.15
J01DD02 Parenteral 1.18 1.02
J01DD04 Parenteral 13.49 14.41
J01DD08 Oral 1.06 0.73
J01DD  15.90 17.58
J01DE01 Parenteral 0.60 0.68
J01DE  0.60 0.68
J01D  16.96 18.52
J01DH02 Parenteral 1.88 2.71
J01DH51 Parenteral 1.56 0.30
J01DH  3.44 3.01
J01EE01 Oral 0.00 0.59
J01E  0.00 0.59
J01FA03 Oral 0.00 0.11
J01FA10 Oral 1.97 0.81
J01FA  1.97 0.92
J01FF01 Parenteral 0.06 0.06
J01FF02 Parenteral 0.29 0.00
J01FF  0.35 0.06
J01GB03 Parenteral 0.13 0.18
J01GB06 Parenteral 3.21 3.50
J01G  3.35 3.68
J01MA02 Parenteral 0.20 0.24
J01MA02 Oral 1.79 0.22
J01MA  1.98 0.46
J01MB04 Oral 0.00 0.18
J01M  1.98 0.64
J01XA01 Parenteral 1.57 0.79
J01XA02 Parenteral 0.00 0.07
J01XA  1.57 0.86
J01XB01 Parenteral 0.59 0.73
J01XB  0.59 0.73
J01XD01 Oral 0.00 0.04
J01XX08 Parenteral 0.00 0.05
J01XX  2.15 1.68
TOTAL  33.65 31.37
Table 1: Departments and number of hospitalized patients
Departments No of beds From 1.01.
to31.3.2018
From 1.01.
to31.3.2019
Intensive care 18 49 42
Oncology 14 53 49
Hematology 12 116 129
Cardiology with rheumatology 14 128 136
Endocrinology and genetics 12 178 339
Pulmonology A 14 185 109
Pulmonology B 12 103 116
Immunology 14 151 134
Gastroenterohepatology 12 118 141
Infant, metabolism, and cystic fibrosis 14 135 119
Neurology 12 146 137
Neonatology 17 111 96
Nephrology 12 135 90
Total 177 1608 1637
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in the first quarter of the year 2018 and 2019, 0.06 
DDD/100BD, but important declination of lincomycin 
use was noticed and this antibiotic is not utilized in 2019. 
Concerning aminoglycosides, there was a small increase 
from 3.35 DDD/100BD in 2018 versus 3.68 DDD/100BD 
in 2019, with comparable consumption of gentamicin 
and amikacin in both years. Significant declination of 
quinolone consumption was confirmed in the evaluated 
period from 1.98 DDD/100BD to 0.64 DDD/100BD in the 
first quarter of 2018 and 2019, respectively, which could 
be result of most recent findings and recommendations 
regarding restrictions of quinolone indication field and 
limited prescription of this antibiotic group addressed by 
European Medicinal Agency (EMA) and Food and Drug 
Administration (FDA). From the group of glycopeptide 
Discussion
Republic of North Macedonia has recently 
witnessed a nationwide outbreak of measles. In 
the first quarter of 2019 at the University Clinic for 
pediatric diseases, 138 children were hospitalized 
with respiratory complications (bronchopneumonia) 
induced by measles infection. Pneumonia is the most 
common severe complication of measles and is treated 
with ceftriaxone, while more complicated cases were 
treated with additional vancomycin and azithromycin. It 
should be considered that this fact has an impact on the 
results on antibiotic consumption in 2019.
It is intuitive that antibiotic resistance is 
predominantly confirmed in environments with high 
antibiotic consumption [17], [18], [19]. The overall usage 
and use of different classes of antibiotics in hospitals in 
Europe vary considerably. Results from 30 European 
countries regarding antibacterials consumption for 
systemic use (ATC group J01) that included 139 
hospitals have confirmed that the median use was 49.6 
DDD/100BD, whereas, in Southeast Europe, the median 
use was 42.3 DDD/100BD. The encouraging fact is that 
the results from this study are lower than the median 
values in Europe confirmed in 2001, which indicates the 
improvement of rational antibiotic consumption [20].
Only a few studies were conducted for 
antibiotic consumption in hospitals in the Balkan region 
Figure 1: Comparison of antibiotics consumption in the University 
Clinic for Pediatric Diseases in Skopje in the first quarter of 2018 
versus the first quarter of 2019
antibiotics, serious declination of vancomycin 
consumption was confirmed from 1.57 DDD/100BD 2018 
to 0.79 DDD/100BD in 2019. Teicoplanin was introduced 
in 2019 and it reached a share of 0.07 DDD/100BD of 
antibiotics consumption in the first trimester in this year. 
The consumption of polymyxins (colistin) increased 
from 0.59 to 0.73 DDD/100BD, as well as consumption 
of imidazole derivatives (metronidazole for 0.04 
DDD/100BD) and linezolid for 0.05 DDD/100BD (data 
presented in Figure 1).
The results show that the consumption of 
cephalosporins was 50.39% in the first quarter of 
2018, rising up to 59.99% in the first quarter of 2019. 
Widening in the group of sulfonamides (up to 1.84%) and 
aminoglycosides (from 9.95% to 11.45%) consumption 
was confirmed in the evaluated first trimesters in the year 
2018 versus 2019. Important decrease in dispensing 
share was confirmed for the group of carbapenems from 
10.23% in 2018 to 9.38% in 2019, for penicillins from 
10.24% to 7.06% in 2018 compared to the same trimester 
in 2019, for the group of quinolones from 5.9% to 2.01%, 
and same declination for glycopeptide antibiotics from 
4.66% to 2.68%. In addition, decrease in consumption 
was proofed for the macrolides from 5.86 to 2.86% in 
the same evaluated period (data presented in Figure 2).
Figure 2: Percentage dispensing share of antibiotics in the University 
Clinic for Pediatric Diseases in Skopje in the first quarters of 2018 
versus 2019
 Sadikarijo et al. Antibiotic Consumption in Hospitalized Children
Open Access Maced J Med Sci. 2020 Jun 10; 8(E):405-410. 409
in recent years. The results from the study conducted at 
the Pediatric Clinic in Novi Sad in 2010 confirmed that 
antibiotic consumption was 35.48 DDD/100BD, with the 
highest share of a class of parenteral cephalosporin 
consumption with 9.89 DDD/100BD and ceftriaxone 4.88 
DDD/100IBD [21]. The same trend was established for 
the parenteral cephalosporin consumption with 14.84 
DDD/100BD in 2018, rising up to 17.58 DDD/100BD in 
2019 at the University Clinic for pediatric diseases.
In the year 2018, we have confirmed that 
penicillin’s and carbapenems consumption are second 
in consumption share in the University Clinic for pediatric 
diseases with 3.44 DDD/100BD in 2018 decreased 
to 2.27 DDD/100BD in 2019 followed by the group of 
aminoglycosides with 3.35 DDD/100BD in 2018 and 
approximately same values of 3.68 DDD/100BD in 2019. 
The group of macrolides has the same consumption 
in both years of 1.97 DDD/100BD. Quinolones have 
consumption of 0.68 in 2018 and 0.92 DDD/100BD in 
2019, respectively. Our data are comparable with data 
on antibiotic consumption in Republic of Croatia (23).
The results obtained through an organization 
called Iskra that collects and processes data for 
antibiotics consumption in the Republic of Croatia 
confirmed that annual consumption of antibiotic 
consumption in the Republic of Croatia in the period 
from 2010 to 2017 is 42.34±1.7 DDD/100BD [22]. The 
most frequently dispensed antibiotics are the group of 
cephalosporins 13.23±0.75 DDD/100BD, followed by 
the group of penicillin with an average of 12.34±0.47 
DDD/100BD, macrolides3.17±0.15 DDD/100BD, and 
aminoglycosides 2.41±0.26 DDD/100BD, the same 
pattern as in the pediatric clinic in the Republic of North 
Macedonia in the year 2019.
Data on hospital antibiotic consumption in 
Croatia for 2017 ranges from 26.5 to 139.5 DDD/100BD, 
average 45,30 DDD/100BD. In comparison, the results 
from the University Clinic for pediatric diseases show 
reduced consumption of the antibiotics, while the 
same class of antibiotics – cephalosporins of the third 
generation – is the most frequently dispensed antibiotics 
in both studies.
Most recent relevant results obtained from 
the hospital in Canton Sarajevo in Bosnia and 
Hercegovina revealed that antimicrobial consumption 
in 2016 was 41.13 DDD/100BD and has raised up to 
45.55 DDD/100BD in 2017. In both years, the group 
of cephalosporins was the most frequently dispensed 
antibiotics, but the first generation of cephalosporins has 
the highest consumption, which is the main difference 
to the results from The University Clinic for Pediatric 
Diseases where the third generation of cephalosporins 
was on the first place for consumption [23].
The results from the European Surveillance 
of Antimicrobial Consumption Network (ESAC-Net) in 
the period from 2000 to 2014 confirmed that antibiotic 
consumption has mostly increased in England, 
Belgium, Ireland, and Greece and that consumption 
trends were not permanent and they change during the 
evaluated period [24]. The differences in the extent of 
antibiotics consumption among the countries depend 
on different antibiotic consumption policies, differences 
in prescription habits, patient population, antibiotic 
resistance, as well as measures applied for evaluation 
of antibiotics consumption. Mechanisms for rational 
antibiotics consumption are applied worldwide as 
a restrictive approach with a limited list of antibiotics 
as well as guidance for the physicians for rational 
prescription and administration [25]. Recognizing the 
factors that influence drug prescription habits and 
conducting studies to monitor bacterial resistance are 
one way to obtain relevant data and provide adequate 
information on the effectiveness of antibiotics, which 
allows prescribing the most appropriate therapy.
Conclusion
The benefits of monitoring the antibiotic 
prescribed pattern are critical due to the fact that they 
provide adequate data on consumption of antibiotics 
and adherence to guidelines. Reduction in total antibiotic 
consumption with ATC code J01 for the first quarter 
(3 months – January, February, and March) in the year 
2019 of 32.09 DDD/100BD was confirmed compared 
to the same period in 2018 at the University Clinic for 
Pediatric Diseases in Skopje is 33.65 DDD/100BD. The 
most consummated antibiotics in the 1st trimester of both 
years were the group of cephalosporins, especially the 
3rd- and 4th-generation parenteral cephalosporins with 
from 16.96 to 19.25 DDD/100BD in the evaluated period 
due to measles outbreak. Decrease of penicillin’s, 
carbapenems, macrolides, and quinolones was 
confirmed in the analyzed period. The most commonly 
used drugs remain ceftriaxone followed by amikacin in 
2019 but azithromycin administrated orally significantly 
declined. The third most commonly utilized antibiotic in 
first quarter of 2019 become meropenem, antimicrobial 
drug from the group of carbapenems.
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